Top of page
Global Site Navigation

Centre for Precision Health - ECU Strategic Research Centre

Centre for Precision Health - ECU Strategic Research Centre
Local Section Navigation
You are here: Main Content

Partner with us

The Centre has a demonstrated track record for innovation, IP development and commercialisation, including the development of Melanoma diagnostics (MelDx), world leading liquid biopsy research for cutaneous and ocular melanoma, development of the Suboptimal Health Status instrument and Alzheimer's Disease diagnostics and polygenic risk score development.

The Centre includes members with well-established roles and relationships with key stakeholders and custodians of several rich clinical data and biospecimen resources, both established and emerging:

  • the Busselton Healthy Ageing Study (BHAS)
  • the Australian Imaging Biomarker and Lifestyle Study of Ageing (AIBL)
  • the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
  • the Raine Study
  • the UK Biobank
  • Cancer Registry
  • the China Suboptimal Health Status Study (COACS)
  • the MSWA funded Systematic Profiling in Neurologic Disorders (SPIN)
  • the WA Melanoma Biomarker Study

Why partner with us?

Partnering with the Centre not only offers the potential to access these resources, and associated in-depth knowledge of them, but to combine this with a demonstrated track record for innovation, IP development and commercialisation which provides the capacity, knowledge and proven experience to continue developing high-quality novel and innovative projects and research outputs. Further it provides the opportunity for academic and industry partners to develop or validate unique and novel ideas/techniques in collaboration with SRCPH researchers.

Past collaborations

The attractiveness of such rich datasets to industry is evidenced by past/current industry collaborations (e.g. Pfizer, Eisai, AbbVie, MSD, Bioyong) and a proven track record of developing and driving effective collaborations with local, national and international academics, including notable collaborative grants, including two EU programs (Horizon 2020), multiple JPND-NHMRC grants, NIH programs of research and Cooperative Research Centres.

Skip to top of page